Kalaris Therapeutics, Inc.
About Kalaris Therapeutics, Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2019
- $165.0K
- Net income
- -$43.4M
- Total assets
- $121.7M
- Market cap
- $105.6M
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $105.6M
- Shares outstanding
- 25.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 19, 2025
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $43.4M in FY2019.
- Trading 62% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Kalaris Therapeutics, Inc..
Write a review
News about Kalaris Therapeutics, Inc.
News & sentiment via Polygon.io
